5-Fluorouracil (5-FU) is the first rationally designed anti-metabolite administered against a variety of solid tumors including BC, where the drug inhibits thymidylate synthase (TS), the key enzyme for de novo synthesis of 2’-deoxythymidine-5’-monophosphate (dTMP) (4). Here, TYMS is linked to breast cancer.